Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Cellectis and Bayer CropScience enter into a collaboration to use Meganuclease technology in plants


Romainville, France and Gent, Belgium - June 30 2006 - Cellectis SA, the rational genome engineering company, and Bayer BioScience NV, a Belgian subsidiary of Bayer CropScience today announced that they have signed an agreement under which Bayer CropScience will have access to Cellectis’ proprietary custom-made Meganuclease technology for use in plant research and to develop products for use in agriculture. Financial terms and conditions were not disclosed.

Meganucleases are a proprietary genome engineering technology developed by Cellectis that allows for highly precise ‘editing’ to genetic sequences. They consist of sequence-specific endonucleases with large (>18-24 bp) recognition sites. This high specificity ensures Meganucleases can bind and cut at a single point in a chosen genome without the imprecision associated with most other forms of gene modification. Custom-made Meganucleases can be designed for very specific gene targeting applications. Bayer CropScience intends to use custom-made Meganucleases in plant research and the development of new products.

'We are delighted to have signed this agreement with Bayer CropScience. We feel it validates Cellectis’ approach of using custom-made Meganucleases for gene targeting in plants' commented Isabelle Pelletier-Bressac, Vice President Business Development of Cellectis, “This agreement once more demonstrates the strong industrial potential of the Meganuclease technology in agriculture”.

'Bayer CropScience strongly believes that the ability to make precise, surgical changes in crop genomes has the potential to be the next break-through enablement for increasing crop yield and creating new plant-based products for our customers. The Cellectis technology can enable us to make such surgical changes in an efficient way.' said Dr. Michiel van Lookeren Campagne, Head of Research for BioScience.


About Bayer CropScience and BioScience NV
Bayer CropScience, a subsidiary of Bayer AG with annual sales of about EUR 6 billion, is one of the world’s leading innovative crop science companies in the areas of crop protection, non-agricultural pest control, seeds and plant biotechnology. The company offers an outstanding range of products and extensive service backup for modern, sustainable agriculture and for non-agricultural applications. Bayer CropScience has a global workforce of about 19,000 and is represented in more than 120 countries. This and further news is available at: www.newsroom.bayercropscience.com

Bayer BioScience NV located in Ghent, Belgium is one of the innovation centers of the BioScience Business Group within Bayer CropScience AG.


About Cellectis SA
Cellectis SA (www.cellectis.com) was founded in 2000, as a spin-off from the Institut Pasteur. Today, Cellectis is the world leader in applying the technology of Meganuclease Recombination Systems to in vivo genome engineering and genome surgery. The company is focused on the research and development of custom-made Meganucleases for in vivo DNA interventions and also provides new tools for rational reverse genetics and targeted recombination. Cellectis develops Meganucleases that can induce unique site-directed double-strand breaks in a living cell, and can be used for biotechnological and therapeutic applications. The company is focusing on bringing 'genome surgery' to clinic as a genuine new molecular medicine approach.


Further Information:
David Sourdive
Chief Operating Officer
Cellectis
t: +33 (0)1 41 83 99 00
e: sourdive@cellectis.com
www.cellectis.com


Annette Josten
Spokeswoman, Corporate Communications
Bayer CropScience
t: +49 (0)2173 38 5788
e: annette.josten@bayercropscience.com
www.bayercropscience.com


Douglas Pretsell
Account Director, Munich Bureau Chief
Northbank Communications
t : +49 (0)89 57 00 18 06
e: d.pretsell@northbankcommunications.com

Notes to editors
Meganucleases are molecules that target a highly specific (one cut every of 1014<


Publisher Contact Information:

Cellectis
+33 (0)1 41 83 99 00
sourdive@cellectis.com

Company profile of Cellectis
Past press releases of Cellectis.

Data


27,526
Tech investments
From our Online Data Service
17,759
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 25€24.0MInternet commerce
Nov 8N/AOther Computers & Electronics
Nov 5€2.1MAudio/Video
Nov 5€5.2MOther Computers & Electronics
Nov 5€0.4MInternet services
Nov 5€1.3MSecurity
Nov 5€1.5MAudio/Video

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Sep 30
TetaVi
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Mar 31
CompPair
the fit allocates chf 100'000 to comppair technologies

Jan 29
Yumpingo
yumpingo raises $10m to transform guest experiences in restaurants





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.